pharma · Cerebral adrenoleukodystrophy (cALD) · Adrenoleukodystrophy
Minoryx Therapeutics S.L.
Minoryx Therapeutics S.L is a pharma organization headquartered in EU. Primary therapeutic focus areas include Cerebral adrenoleukodystrophy (cALD), Adrenoleukodystrophy, Rett Syndrome, CEREBRAL X-LINKED ADRENOLEUKODYSTR
Phase 1 · small molecule · Adrenoleukodystrophy
MT-1-02 (leriglitazone) is a small-molecule oral therapeutic candidate being developed by Minoryx Therapeutics S.L. for adrenoleukodystrophy (ALD), a rare, progressive neurological disorder. The program is currently in Phase 1 development, with the most recent disclosed milestone being a Phase 1, open-label, single-cen
Internal code MT-1-02
MT-1-02 (leriglitazone) is a small-molecule oral therapeutic candidate being developed by Minoryx Therapeutics S.L. for adrenoleukodystrophy (ALD), a rare, progressive neurological disorder. The program is currently in Phase 1 development, with the most recent disclosed milestone being a Phase 1, open-label, single-center drug-drug interaction study evaluating leriglitazone in combination with gemfibrozil, itraconazole, and carbamazepine, as well as food-effect assessment in healthy male subjects. The mechanism of action and specific molecular target have not yet been disclosed. Minoryx's development strategy appears focused on characterizing the pharmacokinetic profile and safety of leriglitazone in early clinical stages. The regulatory status outside Phase 1 clinical trials remains not yet disclosed. No projected peak sales, consensus positioning, or expected next milestone dates have been publicly communicated. The program represents an early-stage investigational approach to a severe, unmet medical need in a rare disease population.
Adrenoleukodystrophy is a rare, inherited metabolic disorder characterized by progressive demyelination of the central and peripheral nervous systems, leading to severe neurological disability and premature mortality. The cerebral form (CALD) is particularly devastating in pediatric populations. Current therapeutic options are limited, and the disease remains a significant unmet medical need with no disease-modifying pharmacological treatments widely available. The rarity of ALD creates a specialized market, but the severity of the condition and lack of effective therapies make any novel mechanism potentially valuable to affected patients and caregivers.
Minoryx's portfolio includes MIN-102, a Phase 3 candidate also targeting ALD, suggesting the company has prioritized this indication as a strategic focus. The competitive landscape includes other investigational programs such as VK0214 (Viking Therapeutics, Phase 1) and vitamin D3-based approaches (Phase 1), indicating emerging interest in novel mechanisms for ALD. Early characterization of leriglitazone's drug-drug interactions and food effects is essential for defining the clinical development path and potential patient populations, particularly given the likelihood of polypharmacy in ALD management.
Drug Class: Small-molecule oral therapeutic
Modality: Small molecule
Route of Administration: Oral
Mechanism of Action: Not yet disclosed
Molecular Target: Not yet disclosed
Indication: Adrenoleukodystrophy (ALD)
Related Therapies in Development: MIN-102 (Minoryx, Phase 3, ALD); VK0214 (Viking Therapeutics, Phase 1, ALD); vitamin D3-based approaches (Phase 1, ALD)
First Approval: Not applicable; program remains in Phase 1
Patent Status: Not yet disclosed
Also known as: ABCD1 deficiency, ALD, Bronze-Schilder disease, Siemerling-Creutzfeldt disease, X-ALD, X-Linked Adrenoleukodystrophy
Prevalence: Point prevalence: 1-9 / 1 000 000 (Norway) — source: Orphanet, validated.
A peroxisomal disorder resulting in cerebral demyelination, axonal dysfunction in the spinal cord leading to spastic paraplegia, adrenal insufficiency and in some cases testicular insufficiency.
ClinicalTrials.gov lists 16 registered studies for X-linked Adrenoleukodystrophy (AACT aggregate).
Phase breakdown: NA (12), PHASE1 (2), PHASE1/PHASE2 (1), PHASE2 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0018544), Orphanet — adrenoleukodystrophy, NCT01165060, NCT01594853, NCT01787578, NCT02233257, NCT02595489, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Phase 1 DDI and Food-Effect Study
Open-label, single-center study evaluating drug-drug interactions with gemfibrozil, itraconazole, and carbamazepine, and food-effect on oral leriglitazone in healthy male subjects.
The adrenoleukodystrophy therapeutic landscape remains sparsely populated with investigational agents. Minoryx Therapeutics is advancing two distinct programs: MIN-102 (Phase 3, small-molecule) and an unnamed Phase 2 study in pediatric CALD patients assessing disease progression prior to hematopoietic stem cell transplant (HSCT). This dual-program strategy suggests Minoryx views ALD as a core therapeutic area. Viking Therapeutics' VK0214 (Phase 1, small-molecule) represents an alternative investigational mechanism at an earlier stage. Vitamin D3-based therapies (Phase 1) represent a distinct pharmacological approach. The Phase 1 status of leriglitazone positions it behind MIN-102 in Minoryx's own pipeline, suggesting either complementary mechanisms or sequential development strategies. The limited competitive field reflects both the rarity of ALD and the high barriers to drug development in orphan neurological diseases.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| The MIN-102 Placebo is supplied as an oral suspension with similar appearance to MIN-102 drug product. MIN-102 placebo oral suspension is packaged in an amber glass bottle with filled volume based on the required clinical dose. | Minoryx Therapeutics S.L. | small_molecule | phase_3 |
| AN OPEN-LABEL, MULTICENTER STUDY IN MALE PEDIATRIC PATIENTS WITH CEREBRAL X-LINKED ADRENOLEUKODYSTROPHY (CALD) TO ASSESS THE EFFECTS OF MIN-102 TREATMENT ON DISEASE PROGRESSION PRIOR TO HUMAN STEM CELL TRANSPLANT (HSCT) | Minoryx Therapeutics S.L. | other | phase_2 |
| VK0214 | Viking Therapeutics | small_molecule | phase_1 |
| vitamin D3 | S.L | other | phase_1 |
| PIOGLITAZONE | — | Peroxisome proliferator-activated receptor gamma agonist | Phase 2 |
| LERIGLITAZONE | — | Peroxisome proliferator-activated receptor gamma agonist | Phase 2 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
FDA Status: Not yet disclosed beyond Phase 1 clinical trial designation (NCT 2025-521508-23-00).
EMA Status: Not yet disclosed.
PMDA (Japan) Status: Not yet disclosed.
NMPA (China) Status: Not yet disclosed.
Approval History: No approvals reported for leriglitazone. Program remains in early clinical development.
Note: Gemfibrozil, used as a comparator drug in the Phase 1 DDI study, is approved in the United States under NDA 018422 and multiple generic ANDA applications from manufacturers including Apotex, Ascent Pharma, Aurobindo, Cadila, Teva, Pfizer, and others.
Leriglitazone is a small-molecule oral therapeutic candidate being developed by Minoryx Therapeutics for adrenoleukodystrophy (ALD), a rare inherited neurological disorder characterized by progressive demyelination and neurological disability.
Leriglitazone is in Phase 1 clinical development. The most recent disclosed milestone is a Phase 1, open-label, single-center study evaluating drug-drug interactions and food-effect in healthy male subjects.
Minoryx Therapeutics S.L. is the sponsor and developer of leriglitazone (MT-1-02).
The mechanism of action and molecular target of leriglitazone have not yet been disclosed by the sponsor.
Adrenoleukodystrophy is a rare, inherited metabolic disorder causing progressive demyelination of the nervous system, leading to severe neurological disability and premature mortality. Current therapeutic options are limited, making it a significant unmet medical need.
Leriglitazone is administered orally.
NCT 2025-521508-23-00 is a Phase 1, open-label, single-center study evaluating drug-drug interactions with gemfibrozil, itraconazole, and carbamazepine, and food-effect on leriglitazone in healthy male subjects.
No, leriglitazone has not been approved by the FDA or any other regulatory agency. It remains in Phase 1 clinical development.
Minoryx is also developing MIN-102, which is in Phase 3 development for ALD, and is conducting a Phase 2 study in pediatric CALD patients assessing disease progression prior to hematopoietic stem cell transplant.
Yes, VK0214 (Viking Therapeutics, Phase 1) and vitamin D3-based approaches (Phase 1) are also in development for ALD, though the competitive field remains limited.
Drug-drug interaction studies are standard in early-stage development to characterize how leriglitazone interacts with other medications. The selection of gemfibrozil, itraconazole, and carbamazepine suggests anticipated polypharmacy in ALD patients.
No projected approval timeline or expected next milestone date has been disclosed by Minoryx.
No partnership or license agreement has been disclosed for leriglitazone.
Projected peak sales have not been disclosed.
Leriglitazone is being developed for adrenoleukodystrophy, a rare disease affecting both pediatric and adult populations, though the specific target population for this candidate has not been fully defined.
Expected next milestones and development steps have not been disclosed. Completion of the Phase 1 DDI study and potential advancement to Phase 2 efficacy trials would represent logical next steps.
MT-1-02 → Drug → Target → Indication → Company → Trials → Competitors
Strategic Positioning: The Phase 1 DDI and food-effect study represents standard early-stage pharmacokinetic characterization necessary to inform Phase 2 trial design and patient dosing strategies. The selection of gemfibrozil, itraconazole, and carbamazepine as DDI substrates suggests anticipated polypharmacy in the target patient population, consistent with ALD management complexity.
Competitive Implications: Leriglitazone's Phase 1 status places it significantly behind MIN-102 (Phase 3), Minoryx's lead ALD program. This suggests leriglitazone may represent either a backup candidate or a distinct mechanism for a specific ALD subpopulation. The sparse competitive field (VK0214 at Phase 1; vitamin D3 at Phase 1) indicates limited near-term competitive pressure but also reflects the difficulty of ALD drug development.
Future Catalysts: Completion of the Phase 1 DDI study and publication of pharmacokinetic data; advancement to Phase 2 efficacy studies; regulatory feedback on development pathway; potential partnership or licensing announcements.
Expected Milestones: Timing of Phase 2 initiation, efficacy endpoints selection, and patient population definition remain not yet disclosed.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.